Giant Papillary Conjunctivitis
- Author: Barry A Weissman, OD, PhD, FAAO; Chief Editor: Hampton Roy, Sr, MD more...
Giant papillary conjunctivitis is a common complication of contact lens wear. It has also been called contact lens–induced papillary conjunctivitis (CLPC). Spring first described giant papillary conjunctivitis in association with contact lens use,[1, 2, 3] which is hypersensitivity-related inflammation of the ocular tarsal palpebral conjunctivae. (See Etiology, History, and Physical Examination.)
Prior to the popularization of hydrogel (soft) contact lenses over the past 4 decades, such reactions were primarily seen as immunoglobulin E (IgE)–mediated ocular allergies: allergic conjunctivitis (AC) or vernal keratoconjunctivitis (VKC). VKC is a seasonal, atopic disease in young people (more common in boys) that occasionally becomes severe and leads to shield corneal ulcers and other complications. Giant papillary conjunctivitis related to contact lens wear, however, never leads to the severe tissue morbidity of VKC. (See Prognosis.)
Giant papillary conjunctivitis symptoms and signs, such as papillary changes in the tarsal conjunctiva, have been associated with the use of all types of contact lenses (eg, rigid, hydrogel, silicone hydrogel, piggyback, scleral, prosthetic). (See History and Physical Examination.)
Similar reactions have been noted with ocular prostheses, extruding scleral buckles, exposed ocular sutures, and even elevated corneal scars. The initially small papillae eventually coalesce with expanding internal collections of inflammatory cells. When the lesions reach a diameter of more than 0.3 mm, often approaching or exceeding 1 mm, the condition is referred to as giant papillary conjunctivitis. Images of eyelid papillae appear below. (See Etiology.)
Because of the high prevalence of giant papillary conjunctivitis in contact lens wearers, every patient who wears contact lenses should be considered as a potential patient with giant papillary conjunctivitis.
See the following for more information:
The antigen(s) responsible for giant papillary conjunctivitis have yet to be identified. From circumstantial evidence, the initiating event is believed to be mechanical irritation and/or antigenic stimulus of the tarsal conjunctiva of the upper lids, perhaps by a contact lens surface or edge (rigid or flexible) or deposit, followed by histologic changes in the tissue (mast cell degranulation and typical secondary inflammatory cascade). This leads to conjunctivitis and further tissue changes and increasing inflammatory markers in the tears.
Debris on the surface of contact lenses may be a cause as well as a result, leading to a spiral of inflammation that causes more lens deposits to form, leading to additional inflammation.[1, 2, 3]
All forms of ocular prostheses, including rigid and hydrogel contact lenses and artificial glass eyes, as well as extruding scleral buckles, exposed portions of sutures, filters, knots, and even corneal scars, can cause giant papillary conjunctivitis.
Heat sterilization, poor cleaning, thick or rough contact lens edges, and extended wearing times favor the development of giant papillary conjunctivitis.
First-generation silicone hydrogel contact lenses may be more prone to giant papillary conjunctivitis development, perhaps because of their mechanical stiffness or their higher propensity for lipid deposition. Silicone hydrogel lenses tend to induce more local giant papillary conjunctivitis (similar to the changes seen with rigid lenses), whereas hydrogel lenses tend to induce more generalized giant papillary conjunctivitis reactions in the palpebral conjunctiva.
In the United States, hydrogel contact lenses appear to result in an overall prevalence of giant papillary conjunctivitis of approximately 20%, whereas rigid contact lens wear appears to result in a prevalence of approximately 5%. One study found that 85% of 221 patients with giant papillary conjunctivitis had been wearing soft (hydrogel) lenses, whereas only 15% used rigid lenses. With an increased frequency of contact lens replacement from more than four weeks to less than four weeks, the incidence of giant papillary conjunctivitis has dropped from 36% to 4.5%.
The international prevalence of giant papillary conjunctivitis is similar to that in the United States.
Both sexes develop giant papillary conjunctivitis.
Giant papillary conjunctivitis can be more aggressive in children who wear contact lenses.
The prognosis in giant papillary conjunctivitis is good. Approximately 80% of patients can return to comfortable contact lens wear with appropriate treatment.
Ptosis of the upper lids and decreased contact lens tolerance can occur. Giant papillary conjunctivitis has been a common cause for temporary and permanent contact lens intolerance.
The lids of some patients return to normal appearance following the resolution of giant papillary conjunctivitis, whereas other lids retain small, white, capped scars of the giant papillary lesions for long periods, sometimes indefinitely.
Giant papillary conjunctivitis is not associated with mortality.
Patients should be educated about appropriate contact lens cleaning and follow-up care. Patients should be advised to return for regular professional evaluations (perhaps once or twice a year if no other complications) and to make additional appointments if they experience any increasing ocular itching, mucous discharge, or dirty contact lenses.
Patients should also be educated about the chronic nature of this disease and its symptoms (eg, ocular itch, mucous discharge, contact lens intolerance) and should be counseled to present within a week of any relapsing symptoms.
Allansmith MR, Korb DR, Greiner JV. Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology. 1978 Aug. 85(8):766-78. [Medline].
Allansmith MR, Ross RM. Giant papillary conjunctivitis. Int Ophthalmol Clin. 1988. 28(4):309-16.
Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am. 2008 Feb. 28(1):83-103, vi. [Medline].
Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012 Nov. 67 (11):1327-37. [Medline].
Forister JF, Forister EF, Yeung KK, Ye P, Chung MY, Tsui A, et al. Prevalence of contact lens-related complications: UCLA contact lens study. Eye Contact Lens. 2009 Jul. 35(4):176-80. [Medline].
Dunn JP Jr, Weissman BA, Mondino BJ, Arnold AC. Giant papillary conjunctivitis associated with elevated corneal deposits. Cornea. 1990 Oct. 9(4):357-8. [Medline].
Skotnitsky CC, Naduvilath TJ, Sweeney DF, Sankaridurg PR. Two presentations of contact lens-induced papillary conjunctivitis (CLPC) in hydrogel lens wear: local and general. Optom Vis Sci. 2006 Jan. 83 (1):27-36. [Medline].
Donshik PC, Ballow M, Luistro A, Samartino L. Treatment of contact lens-induced giant papillary conjunctivitis. CLAO J. 1984 Oct-Dec. 10(4):346-50. [Medline].
Tagliaferri A, Love TE, Szczotka-Flynn LB. Risk factors for contact lens-induced papillary conjunctivitis associated with silicone hydrogel contact lens wear. Eye Contact Lens. 2014 May. 40 (3):117-22. [Medline].
Allansmith MR, Korb DR, Greiner JV, Henriquez AS, Simon MA, Finnemore VM. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol. 1977 May. 83(5):697-708. [Medline].
Irani AM, Burtus I, Tabbar KF, et al. Human conjunctival mast cells; distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol. 1990. 86(1):34-40.
Greiner JV, Covington HI, Allansmith MR. Surface morphology of the human upper tarsal conjunctiva. Am J Ophthalmol. 1977 Jun. 83(6):892-905. [Medline].
Abelson MB, Soter NA, Simon MA, Dohlman J, Allansmith MR. Histamine in human tears. Am J Ophthalmol. 1977 Mar. 83(3):417-8. [Medline].
Donshik PC, Ballow M. Tear immunoglobulins in giant papillary conjunctivitis induced by contact lenses. Am J Ophthalmol. 1983 Oct. 96(4):460-6. [Medline].
Ballow M, Donshik PC, Mendelson I. Complement proteins and C3 anaphylatoxin in the tears of patients with contact lens associated conjunctivitis. J Allergy Clin Immunol. 1985. 76(3):473-6.
Szczotka LB, Cocuzzi E, Medof ME. Decay-accelerating factor in tears of contact lens wearers and patients with contact lens-associated complications. Optom Vis Sci. 2000 Nov. 77(11):586-91. [Medline].
Ballow M, Donshik PC, Rapacz P, Samartino L. Tear lactoferrin levels in patients with external inflammatory ocular disease. Invest Ophthalmol Vis Sci. 1987 Mar. 28(3):543-5. [Medline].
Rapacz P, Tedesco J, Donshik PC, Ballow M. Tear lysozyme and lactoferrin levels in giant papillary conjunctivitis and vernal conjunctivitis. CLAO J. 1988 Oct-Dec. 14(4):207-9. [Medline].
Elgebaly SA, Donshik PC, Rahhal F, Williams W. Neutrophil chemotactic factors in the tears of giant papillary conjunctivitis patients. Invest Ophthalmol Vis Sci. 1991 Jan. 32(1):208-13. [Medline].
Irkeç MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm. 1999 Mar. 7(1):35-8. [Medline].
Moschos MM, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses. Cornea. 2004 Nov. 23(8):771-5. [Medline].
Zhong X, Liu H, Pu A, Xia X, Zhou X. M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis. Arch Immunol Ther Exp (Warsz). 2007 May-Jun. 55(3):173-7. [Medline]. [Full Text].
Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R, Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res. 1993 Apr. 12(4):313-21. [Medline].
Khurana S, Sharma N, Agarwal T, Chawla B, Velpandian T, Tandon R, et al. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens. 2010 Jul. 36 (4):210-4. [Medline].
Diao H, She Z, Cao D, Wang Z, Lin Z. Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis. Adv Ther. 2012 Jul. 29 (7):645-53. [Medline].
Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea. 2008 Feb. 27 (2):228-9. [Medline].
Korb DR, Greiner JV, Finnemore VM, Allansmith MR. Treatment of contact lenses with papain. Increase in wearing time in keratoconic patients with papillary conjunctivitis. Arch Ophthalmol. 1983 Jan. 101(1):48-50. [Medline].
Kruger CJ, Ehlers WH, Luistro AE, Donshik PC. Treatment of giant papillary conjunctivitis with cromolyn sodium. CLAO J. 1992 Jan. 18(1):46-8. [Medline].
Spring TF. Reaction to hydrophilic lenses. Med J Aust. 1974 Mar 23. 1(12):449-50. [Medline].
Porazinski AD, Donshik PC. Giant papillary conjunctivitis in frequent replacement contact lens wearers: a retrospective study. CLAO J. 1999 Jul. 25 (3):142-7. [Medline].